Compare HLNE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLNE | TVTX |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2017 | 2013 |
| Metric | HLNE | TVTX |
|---|---|---|
| Price | $102.77 | $65.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $156.78 | $40.62 |
| AVG Volume (30 Days) | 623.7K | ★ 1.6M |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 41.64 | ★ 92.89 |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $758,993,000.00 | N/A |
| Revenue This Year | $9.69 | $44.76 |
| Revenue Next Year | $15.81 | $35.51 |
| P/E Ratio | $27.34 | ★ N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $71.88 | $18.13 |
| 52 Week High | $155.66 | $67.85 |
| Indicator | HLNE | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 61.51 |
| Support Level | $98.37 | $53.76 |
| Resistance Level | $106.17 | $66.24 |
| Average True Range (ATR) | 3.59 | 2.00 |
| MACD | -0.56 | -0.05 |
| Stochastic Oscillator | 39.59 | 73.17 |
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.